Skip to main content

Advertisement

Table 1 Summary of Baseline Characteristics

From: Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies

Characteristic Study
  LYCS (n = 105) S012 (n = 212) S013 (n = 21) All (N = 338)
Gender, male, n (%) 76 (72.4) 157 (74.1) 16 (76.2) 249 (73.7)
Age 9.3 (0.08) 8.5 (0.11) 8.0 (0.28) 8.7 (0.08)
ADHD subtype, n (%)     
Combined 74 (70.5) 166 (78.3) 6 (28.6) 246 (72.8)
Inattentive 31 (29.5) 43 (20.3) 15 (71.4) 89 (26.3)
Hyperactive/impulsive 0 (0.0) 3 (1.4) 0 (0.0) 3 (0.9)
Stimulant-naïve, n (%) 105 (100.0) 116 (54.7) 8 (38.1) 229 (67.8)
ADHDRS-IV-PI 37.0 (0.84) 40.5 (0.52) 35.9 (1.13) 39.1 (0.43)
CGI-ADHD-S 4.6 (0.08) 4.8 (0.06) 4.9 (0.10) 4.8 (0.05)
  1. ADHDRS-IV-PI = Attention-Deficit/Hyperactivity Disorder Rating Scale Parent Version: Investigator Administered and Scored; CGI-ADHD-S = Clinical Global Impression of ADHD Severity.
  2. Mean (SE) or numbers (%).